Chemotherapy patients who learned structured memory and attention strategies through a workbook-based training program reported fewer everyday cognitive failures than those who received no intervention, according to controlled trial data. The program, called Memory and Attention Adaptation Training, or MAAT, gave participants practical compensation techniques during brief coaching sessions and phone contacts. A separate line of research has tested whether pairing light exercise with low-dose ibuprofen during active chemotherapy produces similar cognitive benefits, raising the question of whether combining both approaches could yield even stronger results.
Why memory training during chemotherapy matters right now
Cancer treatment has improved survival rates, but the mental fog that often accompanies chemotherapy still disrupts daily life for many patients. Trouble remembering appointments, losing track of conversations, and struggling to focus at work are common complaints. These problems can persist after treatment ends, and until recently, patients had few evidence-tested options beyond waiting for symptoms to fade on their own.
The MAAT program addressed that gap directly. Developed as a structured, strategy-based intervention, it taught chemotherapy recipients specific techniques to compensate for memory and attention difficulties rather than simply hoping for recovery. In the original work describing this approach, researchers outlined how participants used a manualized workbook alongside brief therapy-style sessions to practice skills such as organizing information, using external reminders, and breaking complex tasks into manageable steps.
A natural next question is whether patients who practice MAAT strategies daily while also meeting a modest weekly exercise target would show additive improvements on objective neuropsychological tests compared with either intervention alone. No published trial has tested that exact combination. But the existence of separate research tracks, one focused on cognitive-behavioral training and another on exercise plus anti-inflammatory medication, suggests the scientific community is circling the same hypothesis from different angles.
Trial data supporting MAAT and exercise-based interventions
The strongest evidence for MAAT comes from a waitlist control trial that used validated measures of everyday cognitive failures and complaints. That study reported effect sizes showing the training group improved relative to participants who had not yet received the intervention, according to results published in Psycho-Oncology. Participants who completed the program described fewer lapses in routine tasks, such as missing medication doses or losing items, the kind of real-world improvements that matter when someone is trying to keep working or managing a household during treatment.
On a parallel track, a phase 2 trial tested an exercise program and low-dose ibuprofen versus controls in patients receiving chemotherapy, according to a report in Cancer. That study used a four-arm design to compare exercise alone, ibuprofen alone, the combination of both, and usual care. Cognitive outcomes were measured with the FACT-Cog scale, a widely used questionnaire that captures patients’ perceptions of memory, concentration, and mental sharpness. A related news summary noted that the exercise routine was associated with improvements in attention and overall perceived cognition during treatment.
Separately, a three-arm randomized trial evaluated a broader cognitive rehabilitation program for patients treated with chemotherapy, per a Cancer journal article. That trial included both subjective cognitive complaints measured via FACT-Cog and objective neuropsychological tests that assessed domains such as processing speed and executive function. The inclusion of objective testing is significant because self-reported improvements alone can reflect placebo effects, mood changes, or shifting expectations rather than genuine cognitive gains.
Taken together, these trials establish that structured, non-pharmacologic interventions can produce measurable cognitive benefits during or after chemotherapy. The MAAT research focused on compensatory strategies, teaching patients to work around their limitations by externalizing memory and simplifying demanding tasks. The exercise and ibuprofen research tested whether physical activity and inflammation reduction could protect cognitive function from the start of treatment. Both approaches showed promise on validated outcome measures, though the trial designs, populations, and timing differed enough that direct comparison is difficult.
Open questions about combining strategies and long-term durability
The most pressing gap in the evidence is the absence of any trial testing MAAT-style cognitive training alongside an exercise regimen. Each intervention has been studied in isolation or against passive controls. Whether combining them would produce additive benefits on objective neuropsychological tests, or whether the gains would plateau because the same underlying mechanisms are being targeted, remains an untested hypothesis. The different trial designs complicate matters: the phase 2 exercise trial used a four-arm structure, while the cognitive rehabilitation trial used three arms and emphasized neuropsychological outcomes. These design differences mean that even comparing effect sizes across studies requires caution.
Long-term follow-up data are also limited in the available evidence. The MAAT trials and the exercise studies reported outcomes during or shortly after the intervention period, typically spanning weeks to a few months. Whether patients retained their cognitive gains six months or a year later is not fully addressed in the published sources. For someone deciding whether to invest time in daily memory exercises or regular physical activity during an already exhausting treatment schedule, durability matters as much as short-term benefit.
Another unresolved issue is dose–response. No raw participant-level cognitive test scores or detailed adherence logs from these trials are publicly available in the reviewed sources. That makes it hard to know, for example, whether patients who practiced MAAT techniques more consistently saw proportionally larger benefits, or whether there was a threshold of exercise intensity or frequency below which the physical activity made no difference. Without that information, clinicians must extrapolate from group averages when advising individual patients.
There are also practical questions about implementation outside research settings. Trial participants often receive structured support, including scheduled coaching calls, reminders, and monitoring that may not be feasible in routine oncology practice. It is unclear whether self-guided use of a MAAT-style workbook, without therapist input, would yield similar cognitive gains. Likewise, the supervised exercise protocols used in trials may not translate directly to patients who have limited access to gyms, experience severe fatigue, or face other treatment-related constraints.
What this evidence means for patients and clinicians
For patients currently undergoing chemotherapy and experiencing cognitive difficulties, several practical implications emerge from the existing data. Structured memory and attention training programs like MAAT have been tested in controlled settings and shown benefits on everyday cognitive failures, suggesting that learning compensatory strategies can make day-to-day life more manageable even if underlying brain changes persist. Exercise-based interventions, particularly when started during treatment, appear to support perceived cognitive function and may help preserve attention and mental energy.
Clinicians discussing these options with patients can frame them as complementary, low-risk tools rather than cures. A realistic message is that cognitive training and light-to-moderate exercise are unlikely to eliminate all symptoms of “chemo brain,” but they may reduce the frequency and impact of lapses that interfere with work, caregiving, or independent living. Because the evidence base does not yet define an optimal combination, patients can be encouraged to choose approaches that fit their energy levels, physical abilities, and personal preferences.
Future research will need to address several gaps: head-to-head and combination trials of cognitive training plus exercise, standardized outcome measures that include both self-report and neuropsychological testing, and longer follow-up periods to track durability. As those data emerge, oncology teams will be better positioned to recommend specific, evidence-based packages of support. For now, the existing trials offer a cautiously optimistic message: targeted behavioral strategies, whether focused on the mind, the body, or both, can give chemotherapy patients more control over one of the most frustrating side effects of treatment.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
